Compare CION & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CION | ETON |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 496.0M | 498.8M |
| IPO Year | N/A | 2018 |
| Metric | CION | ETON |
|---|---|---|
| Price | $9.47 | $15.16 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.50 | ★ $29.67 |
| AVG Volume (30 Days) | ★ 442.0K | 208.1K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 12.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $244,923,000.00 | $70,316,000.00 |
| Revenue This Year | N/A | $107.23 |
| Revenue Next Year | N/A | $29.72 |
| P/E Ratio | $19.21 | ★ N/A |
| Revenue Growth | N/A | ★ 102.77 |
| 52 Week Low | $8.51 | $11.09 |
| 52 Week High | $12.71 | $23.00 |
| Indicator | CION | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 35.14 |
| Support Level | $9.30 | $15.09 |
| Resistance Level | $9.74 | $16.00 |
| Average True Range (ATR) | 0.23 | 0.70 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 26.90 | 9.36 |
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.